ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
34.85
-0.14%
US Tech 100
19,245.20
0.42%
S&P 500
5,475.09
0.27%
US Dollar vs CAD
1.37538
0.11%
Bitcoin
63,060.69
0.33%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Lixte Biotechnology Holdings Inc (LIXTW)

  7. Lixte Biotechnology Holdings Inc (LIXTW) News

LIXTW

Lixte Biotechnology (LIXTW)

Lixte Biotechnology Holdings Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:LIXTW
DateTimeSourceHeadlineSymbolCompany
06/14/20241:47PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:LIXTWLixte Biotechnology Holdings Inc
06/14/202410:00AMGlobeNewswire Inc.LIXTE Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical TrialNASDAQ:LIXTWLixte Biotechnology Holdings Inc
06/14/20248:30AMGlobeNewswire Inc.LIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon Cancer Clinical TrialNASDAQ:LIXTWLixte Biotechnology Holdings Inc
06/14/20247:30AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:LIXTWLixte Biotechnology Holdings Inc
06/06/20247:30AMGlobeNewswire Inc.Scientific Journal Reports Findings that Show LIXTE’s Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune SystemNASDAQ:LIXTWLixte Biotechnology Holdings Inc
06/05/20242:55PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:LIXTWLixte Biotechnology Holdings Inc
06/03/20247:30AMGlobeNewswire Inc.LIXTE Biotechnology Holdings Names Distinguished Oncologist Jan Schellens as Chief Medical OfficerNASDAQ:LIXTWLixte Biotechnology Holdings Inc
05/29/20244:29PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:LIXTWLixte Biotechnology Holdings Inc
05/20/20244:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:LIXTWLixte Biotechnology Holdings Inc
05/09/202411:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:LIXTWLixte Biotechnology Holdings Inc
05/09/20247:30AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LIXTWLixte Biotechnology Holdings Inc
05/08/20248:25AMGlobeNewswire Inc.LIXTE Biotechnology Co-Sponsoring International Scientific Conference on “Therapeutic Over-Activation in Cancer”NASDAQ:LIXTWLixte Biotechnology Holdings Inc
04/24/20242:25PMAllPennyStocks.comMixed Shelf Filing Gives Micro Cap Delayed BoostNASDAQ:LIXTWLixte Biotechnology Holdings Inc
03/27/20242:35PMAllPennyStocks.comBiotech Steals The Show Following Pre-Clinical Data AnnouncementNASDAQ:LIXTWLixte Biotechnology Holdings Inc
03/27/20247:30AMGlobeNewswire Inc.NEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE’S LEAD CLINICAL COMPOUND, CAN FORCE CANCER CELLS TO GIVE UP THEIR CANCER-CAUSING PROPERTIESNASDAQ:LIXTWLixte Biotechnology Holdings Inc
03/21/20247:30AMGlobeNewswire Inc.LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer TreatmentsNASDAQ:LIXTWLixte Biotechnology Holdings Inc
02/27/20247:30AMGlobeNewswire Inc.Professor René Bernards to Present New Pre-Clinical Data on LIXTE’s LB-100 at Joint Conference of European and American Associations for Cancer ResearchNASDAQ:LIXTWLixte Biotechnology Holdings Inc
02/26/20247:30AMGlobeNewswire Inc.LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCINASDAQ:LIXTWLixte Biotechnology Holdings Inc
01/29/20247:30AMGlobeNewswire Inc.First Patient Dosed with LIXTE’s LB-100 and GSK’s Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma TrialNASDAQ:LIXTWLixte Biotechnology Holdings Inc
11/13/20237:30AMGlobeNewswire Inc.LIXTE Biotechnology Provides Update on Clinical Progress and Expanding CollaborationsNASDAQ:LIXTWLixte Biotechnology Holdings Inc
10/16/20237:30AMGlobeNewswire Inc.LIXTE, Netherlands Cancer Institute, and Oncode Institute to Expand CollaborationNASDAQ:LIXTWLixte Biotechnology Holdings Inc
10/09/20237:30AMGlobeNewswire Inc.LIXTE Biotechnology Holdings Announces the Passing of its Founder, John S. KovachNASDAQ:LIXTWLixte Biotechnology Holdings Inc
09/26/20237:30AMGlobeNewswire Inc.LIXTE Appoints Bas van der Baan as President and Chief Executive OfficerNASDAQ:LIXTWLixte Biotechnology Holdings Inc
09/20/20237:30AMGlobeNewswire Inc.LIXTE Biotechnology Announces a Supported Collaborative Trial to Study LIXTE’s First-in-Class PP2A Inhibitor, LB-100, Plus GSK’s Immunotherapy, Dostarlimab, in Clear-Cell Ovarian CancerNASDAQ:LIXTWLixte Biotechnology Holdings Inc
07/20/20233:05PMGlobeNewswire Inc.LIXTE Biotechnology Announces Closing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq RulesNASDAQ:LIXTWLixte Biotechnology Holdings Inc
07/18/20237:00AMGlobeNewswire Inc.LIXTE Biotechnology Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq RulesNASDAQ:LIXTWLixte Biotechnology Holdings Inc
07/17/20237:30AMGlobeNewswire Inc.Preclinical Results of LIXTE Biotechnology’s Collaboration with Netherlands Cancer Institute Reveal Novel Mechanism by which LIXTE’s Lead Clinical Compound LB-100 Enhances Effectiveness of Immunotherapy and ChemotherapyNASDAQ:LIXTWLixte Biotechnology Holdings Inc
12/01/202011:30AMGlobeNewswire Inc.Lixte Biotechnology Holdings, Inc. Announces Closing of Public Offering and Uplisting to NasdaqNASDAQ:LIXTWLixte Biotechnology Holdings Inc
11/30/20202:52PMBusiness WireWestPark Capital Announces Closing of $5,700,000 Follow-On Offering & NASDAQ Up-listing of Lixte Biotechnology Holdings, Inc....NASDAQ:LIXTWLixte Biotechnology Holdings Inc
 Showing the most relevant articles for your search:NASDAQ:LIXTW

Your Recent History

USOTC
GSTC
Globestar Therapeutics (PK)
USOTC
EMGE
Emergent Health (PK)
USOTC
GTVH
Golden Triangle Ventures (PK)
NYSE
GME
GameStop
USOTC
TSOI
Therapeutic Solutions (PK)
USOTC
KBLB
Kraig Biocraft Laborator... (QB)
USOTC
ELTP
Elite Pharmaceuticals (QB)
USOTC
VXIT
Virexit Technologies (PK)
USOTC
CNNA
Cann American (CE)
NASDAQ
TSLA
Tesla
USOTC
TPTW
TPT Global Tech (PK)
USOTC
CGAC
Code Green Apparel (PK)
USOTC
RSPI
RespireRx Pharmaceuticals (PK)
USOTC
CYDY
CytoDyn (QB)
USOTC
NNAX
New Momentum (PK)
USOTC
BIEL
Bioelectronics (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved